Intellia Therapeutics (NASDAQ: NTLA)
Intellia Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Intellia Therapeutics Company Info
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
News & Analysis
Top ETFs Tracking CRISPR Gene Editing
These exchange-traded funds track companies in this biotech space.
Investing in Gene-Editing Stocks
Intellia Therapeutics Delivers a Q4 Beat
Intellia Therapeutics reported better-than-expected results for the fourth quarter thanks to a boost in its collaboration revenue.
Down 33% in 1 Month, Should You Buy the Dip With Intellia Therapeutics Stock?
Intellia Tops Revenue Estimates
Intellia Therapeutics reported better-than-expected third-quarter earnings, highlighting advancements in its CRISPR gene-editing technology.
Intellia Therapeutics Just Notched Another Win. So Why Did Its Stock Fall 18% in 1 Day?
There's nothing bearish at all about what it reported recently.
This Beaten-Down Stock Could Soar by 354%, According to Wall Street
Maybe the Street is a bit too optimistic on this one.
The Best CRISPR Companies to Invest In
These CRISPR stocks could be big winners for patient investors.
Valuation
Earnings Transcripts
Intellia Therapeutics, Inc (NTLA) Q3 2021 Earnings Call Transcript
NTLA earnings call for the period ending October 3, 2021.
Intellia Therapeutics, inc (NTLA) Q2 2021 Earnings Call Transcript
NTLA earnings call for the period ending June 30, 2021.
Intellia Therapeutics, Inc. (NTLA) Q1 2021 Earnings Call Transcript
NTLA earnings call for the period ending March 31, 2021.
Intellia Therapeutics, Inc. (NTLA) Q4 2020 Earnings Call Transcript
NTLA earnings call for the period ending December 31, 2020.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.